Abstract | The relationship between blood pressure (BP) and cognitive outcomes in elderly adults has implications for global health care. Both hypertension and hypotension affect brain perfusion and worsen cognitive outcomes. The presence of hypertension and other vascular risk factors has been associated with decreased performance in executive function and attention tests. Cerebrovascular reserve has emerged as a potential biomarker for monitoring pressure-perfusion-cognition relationships. A decline in vascular reserve capacity can lead to impaired neurovascular coupling and decreased cognitive ability. Endothelial dysfunction, microvascular disease, and mascrovascular disease in midlife could also have an important role in the manifestations and severity of multiple medical conditions underlying cognitive decline late in life. However, questions remain about the role of antihypertensive therapies for long-term prevention of cognitive decline. In this Review, we address the underlying pathophysiology and the existing evidence supporting the role of vascular factors in late-life cognitive decline.
Introduction
The relationship between blood pressure (BP) and cogni tive outcomes in the elderly has gained attention because of its implications for global health care. Hypertension affects more than a third of the population worldwide, 1 especially those older than 65 years, of whom 65-75% report having hypertension. 2 The prevalence of asympto matic hypotension in this age group is 16.2%. 3 Both high and low BP have been linked with cognitive decline and dementia. The pathophysiology of the relationship between BP and cognition is unclear, but hypo perfusion and neurodegeneration have emerged as possible under lying mechanisms. [4] [5] [6] [7] The BP levels that should be tar geted to achieve optimal perfusion while preventing cognitive decline are still being debated.
In this Review, we summarize the evidence indicat ing that decline in vascular reserve capacity, which is associ ated with impaired neurovascular coupling, is one of the main pathways linking BP to cognitive decline. We also discuss physiological monitoring and MRI studies that improve our understanding of the pathophysiology linking abnormalities in brain vascular reserve and cog nitive decline, and present supporting clinical evidence for the BP-cognition relationship from epidemiological studies and clinical trials of antihypertensive therapies.
BP and cognition
Both hypertension and hypotension are associated with disruptions in neurovascular coupling, which lead to a decrease in vascular reserve capacity and can cause microvascular disease, stroke, cognitive decline, and dementia. Factors other than perfusion, such as genetic pre disposition, autonomic failure, and neuro degeneration associated with diabetes mellitus, Alzheimer disease, Parkinson disease, and Lewy body disease, have also been proposed to contribute to the progression of dementia, although the mechanisms under lying these associations are still unclear.
BP and brain perfusion
Neurovascular coupling is a concept that refers to the interactions between neurons, vessels and other cells of
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Upon completion of this activity, participants should be able to: 1 Identify clinically relevant biomarkers of brain vascular reserve. 2 Distinguish cognitive domains most likely to be affected by hypertension and examine research into the effects of blood pressure on cognition. 3 Evaluate how antihypertensive therapy may affect cognition.
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the nervous system (such as astrocytes and other glial cells), considered as the basis of the relationship between neuronal activity, hemodynamic factors, and celltocell signaling. 8 These interactions synchronize increases in neuronal activity with perfusion and thus facilitate com munication within the functional networks of the brain. Neurovascular coupling enables redistribution of cere bral blood flow (CBF) to areas of increased activity and metabolic demand, as well as allowing adjustments in response to beattobeat changes in transmural pressure and central autonomic nervous system activity. The three main components of neurovascular regulation are neuro genic, metabolic (mediated by molecules such as o 2 , Co 2 , ATP, and glucose, among others), and myogenic regula tion. Neurogenic regulation refers to tonic and phasic acti vity within the network of the central autonomic nervous system, which includes noradrenergic, serotoninergic, cholinergic, and dopaminergic neuronal activity, and also modulates endothelial function and signaling among neuronal networks. These regulatory systems, which con verge in associative cortical areas, are widely involved in numerous cognitive and motor functions.
Changes in BP are associated with changes in brain per fusion and metabolism. The capacity of the neuro vascular units within vascular territories and of the whole brain to respond to variation in BP and increased metabolic demands is referred to as the brain vascular reserve. endothelial dysfunction associated with advanced age and risk factors such as hypertension and diabetes set the stage for altered neurovascular coupling and regional decline in vasomotor reserve capacity. 9 In this setting, increased oxidative stress and inflammation lower the intrinsic threshold for cell survival. 10 Integration of multiple pathways The combination of advanced age with hypertension and other risk factors provides a background for multi faceted interactions in pathophysiological pathways that lead to cognitive decline and dementia. examples of these pathways are those involved in small vessel disease, altered regulation of blood flow, presence of white matter hyperintensities (WMHs), deposition of amyloid β A4 protein and neurofibrillary tangles, altered cholinergic transmission, and autonomic failure, as well as those resulting from genetic predisposition (such the APOEε4 genotype). These pathways interact in a complex pattern. For example, clearance of amyloid β A4 protein from the brain is dependent on vascular reactivity, which in turn is affected by small vessel disease, whereas the presence of comorbidities associated with small vessel disease may contribute to the pathology of Alzheimer disease. Interactions between multiple pathophysiological path ways result in neuronal death, cortical and subcortical white matter disconnection, and functional decline, 11 primarily in the associative areas of frontal and temporal cortices, which are involved in complex functions such as decisionmaking and memory.
BP has been increasingly linked not only with the pathophysiology of Alzheimer dementia and vascular dementia (the second most common form of dementia, in 12 MCDs are a broader spectrum of preclinical cogni tive (including neurodegenerative) pathologies. 13 The relation ship between BP and these pathologies emphasizes the importance of altered neuro vascular coupling in all of these settings.
14 Nevertheless, the rela tionship between BP and cognition throughout life is still not well understood, with some studies showing a strong associ ation between cognitive decline and hypertension, others showing an associ ation with declining BP, and others showing no such associations. The actual relation ship between BP and cogni tion might be predictable over the course of a lifespan if neuro vascular coupling is con sidered as a hidden variable and the duration of exposure of neurons and cerebral perfusion to fluctuations in BP is assessed. Mounting evidence suggests that the associations between endothelial dysfunction, microvascular disease, and macro vascular disease could have an important role in the manifestations and severity of multiple medical conditions that underlie cognitive decline late in life.
Assessment of vascular reserve
Two biomarkers of vascular reserve are clinically relevant -pressure autoregulation and Co 2 vasoreactivity. 15 Conditions affecting BP regulation are associated with alterations in these markers, which can be assessed with several MRI techniques ( Table 1) .
Autoregulation BP autoregulation maintains a fairly stable perfusion over the range of mean systemic pressures 60-150 mmHg. static autoregulation refers to longterm 'steadystate' control, whereas dynamic autoregulation refers to the adaptation of perfusion to beattobeat variations in intracranial pressure and BP. 16 Numerous conditions, such as hypertension, 17 hypotension, 18 diabetes, 19 vascu lar disease, and stroke, [20] [21] [22] as well as smoking, impair auto regulation. With impaired autoregulation, the sigmoid autoregulation curve that expresses the relation ship between CBF and mean BP becomes more linear and perfusion becomes pressuredependent (Figure 1 ). Hypertension and hypotension alter CBF regulation, and the lower limits of the autoregulation window are shifted toward higher BP values. Therefore, the auto regulation range is narrowed and the slope of the CBF-BP curve becomes steeper. In this setting, vasodilatation in response to low BP can be reduced and vaso constriction in response to high BP can be increased.
orthostatic and postprandial hypotension are defined as a ≥20 mmHg decline in systolic BP when in an upright position, or within 1 h after a meal, respectively. 23 In hypotension syndromes, altered BP regulation leads to supine hypertension. In individuals with hypo tension syn dromes, the mean BP can thus vary with postural change, from 80 mmHg in the upright position to >180 mmHg in the supine position. Accordingly, in these individuals the autoregulated range can be narrowed to ≈20 mmHg 24 when in the upright position, or expanded over a wide range of pressures (mean BP 110-180 mmHg), and the lower autoregulation threshold can be shifted toward high BP values. 18 Therefore, in the setting of hypotension syndromes, the uprightposition BP might be below the range of effective regulation, leading to perfusion decline. In these patients, daily living activities can induce hypo perfusion 25 and lead to syncope, 26 falls, or ischemia and cognitive changes. 27 Transcranial Doppler ultrasonography (TCD) enables noninvasive assessment of dynamic autoregulation from spontaneous fluctuations in BP and CBF velo city 28 at baseline and during postural interventions, such as standing up or headup tilt. 15, 29 CBF fluctuations at 0.01-0.03 Hz have been linked with intracranial pres sure, 30 central sympathetic activity, 31 microcirculation, and cerebral oxygenation. 32 Autoregulation is quantified using mathematical mod eling, Fourier transform analysis, coherence function, and morerecently developed nonlinear methods. 19, [33] [34] [35] A substantial phase lead of CBF velocities with respect to the peripheral BP indicates intact autoregulation. 28, 36, 37 Nonlinear approaches, such as multiple coherence 15 and multimodal pressureflow (MMPF), enable assessment of autoregulation at multiple timescales and have greater sensitivity and specificity for detection of autoregulation defects than linear methods. 19, 35 The MMPF method demonstrates, for example, that hypertension and dia betes substantially impair autoregulation to an observable degree after ischemic stroke ( Figure 2 ReVIews vasoreactivity is calculated as the percent flow change per Co 2 change. TCDbased assessment of vaso reactivity is restricted to CBF velocity measurements in one or two vascular territories. Advances in imaging techniques based on threedimensional continuous arterial spin labeling (3D CAsL) MRI, bloodoxygenleveldependent (BoLD) MRI, and single photon emission computed tomography (sPeCT) imaging, however, enable the assessment of vasoreactivity in anatomical regions and vascular territories (Table 1) . 39 These techniques have advantages over TCD by providing a better assessment of the regional distribution of vasoreactivity, but lack temporal resolution and values need to be averaged over a period of time (a few minutes). Aging, hypertension, diabetes, or stroke reduce vasodilatation 40, 41 in multiple vascular territories, whereas vasoconstriction can be preserved. 42 The variability of CBF responses to patho genic stimuli underscores the importance of underlying small and large vessel disease that can lead to chronic hypo perfusion in numerous brain regions.
Assessment of microvascular disease
Cerebromicrovascular disease associated with hyper tension and other cardiovascular risk factors, includ ing age, is linked with regional hypoperfusion and brain volume loss (Figure 3 ), as well as with neuronal degeneration and cognitive decline in elderly people. [43] [44] [45] [46] [47] [48] Cerebromicrovascular disease accelerates CBF decline with age [49] [50] [51] [52] and is associated with regional differences in vasoregulation and reserve capacity. 9 MRI has enabled the visualization of microvascular disease (that is, lacunar infarctions, microinfarctions, microbleeds, iron deposits, and diffused WMHs) with unprecedented resolution (Figure 4 ). of note, micro infarcts and iron deposits in patients with hyper tension can be visible at ultrahighfield MRI at 8 T, but not at lower resolutions ( Figure 4) . 53 WMHs are associated with global and regional brain atrophy, including hippo campal atrophy; 51 reduced functional neuronal mass, which indicates that an active neurodegenerative process has taken place; 54 lower perfusion 55 and metabolism 56 in the white matter, which affect preferentially frontal, parietal, and temporal cortices; lower oxygenation in the frontal lobes; 57 slower CBF velocities; 58 cognitive decline and executive dysfunction; 59 vascular dementia; [60] [61] [62] motor impairment; 63 and depression. 64 The presence of WMHs was also associated with a 24year increase in diastolic BP (>10 mmHg; odds ratio [oR] 2.6, 95% CI 1.3-5.1), systolic BP (>40 mmHg; oR 2.0, 95% CI 1.2-3.4), pulse pressure (>24 mmHg; oR 1.8, 95% CI 1.1-2.7), and mean arterial pressure (>6 mmHg; oR 2.2, 95% CI 1.4-3.4). (Tables 2-5 ) support the evidence for an agedependent association between BP and decline in cognitive function and/or dementia. specifically, high BP (especially high systolic BP) in middle age is con sistently associated with latelife cognitive impairment and dementia. 58 Therefore, treatment of high sytolic BP during midlife might be an effective strategy to reduce the risk of latelife dementia and cognitive impairment. 66 By contrast, the association between low BP and cognitive dysfunction is more complicated, and is, therefore, less well understood. orthostatic hypo tension in middle age can indicate autonomic failure (a failure in BP regulation causing fluctuations in BP and perfusion during daily living activities), but is a sign of frailty (onset of rapid decline) in old age.
Hypertension and risk of cognitive decline
Hypertension in middle age and cognition A combination of hypertension and other vascular risk factors in the middleaged population could accelerate worsening of cognitive performance late in life (Table 2) . Data from a prospective study of a population 40-69 years old with a 12year followup showed that indivi duals with either central obesity (the uppermost quartile) or hyper tension had poorer performance on executive functioning and visual-motor skills tests (Trail Making Test Part B, and visual Reproduction Immediate and Delayed Recall tests) than other individuals in the population. 67 This associ ation was not observed, however, in leaner indivi duals with hypertension, and neither hypertension nor obesity was individually or synergistically related to verbal memory (immediate or delayed recall). In another study, obesity was related to increased cerebro ascular resistance, slowed CBF velocities, increased systolic BP, and male sex. 68 Hypertension and diabetes were associated with a decline in the ability to perform executive function tasks (Delayed Word Recall Test, Digit symbol substitution Test, and Word Fluency Test) in the ARIC study. 69 In the NHANes III study, 62 70 These findings indicate that a complex composed of several aspects of vascular disease (such as stroke, lacunar infarcts, and WMHs) is linked to deficits in attention and executive function, rather than to a decline in memory (a feature clinically linked with Alzheimer disease). In the ReGARDs crosssectional study, 71 the odds of experienc ing a stroke symptom increased by 35% with each of the following factors: hypertension, diabetes, smoking, lack of exercise, and depressive symptoms; the odds of cognitive impairment increased by 12% with each modifiable factor, in an additive manner. 71 A subsequent analysis of the ReGARDs study showed that an increment of 10 mmHg in diastolic BP, but not systolic BP, was associated with an increased risk (7%) of cognitive impairment. 72 Findings of an inverse association between diastolic or systolic BP and cognitive performance (assessed by a wide range of memory, semantic, and fluency tests) that was inde pendent of age, education, employment grade, smoking status, alcohol consumption, use of antihypertensive medication, diagnosis of diabetes, and cardiovascular disease support the existence of a negative relationship between high BP and cognition. 73 In a study of individuals aged 60-64 years, a large pro portion (71%) of those diagnosed as having MCI reverted to a nonMCI status 4 years later, whereas only 11% of individuals with any MCD reverted to a nonMCD status. 13 Participants with a history of smoking or harmful levels of alcohol consumption, diagnosed but not medi cally treated hypertension, anxiety, or depression, were at increased risk of transitioning to MCI or any MCD. 13 These findings support the notion that modifiable risk factors may contribute to latelife cognitive decline. of note, decreased CBF in middleaged individuals has been linked with worse cognition later in life among patients with hypertension, which indicates that hypoperfusion in middle age might mediate latelife cognitive decline in these individuals. 74 
Hypertension and cognition in the elderly
HYveT 75 and HYveTCoG 7678 enrolled people older than 80 years with uncontrolled hypertension (systolic BP 160-199 mmHg and diastolic BP <110 mmHg; Table 3 ). The median minimental state examination (MMse) score was 26 (maximum 30); the MMse score was higher at younger age, with male sex, higher educational level, higher creatinine and totalcholesterol levels, and lower HDLcholesterol levels. Being either underweight or obese was shown to contribute to decline in MMse scores and was also associated with increased incidence of dementia. 77 of note, lower MMse scores have been associ ated with higher systolic and lower diastolic BP during sitting and standing in another study. 79 In the HYveT study, 75 antihypertensive treatment in elderly patients did not statistically reduce the incidence of dementia. However, this negative finding might have been due to a short followup, owing to the early termi nation of the trial after reductions in mortality and inci dence of stroke were demonstrated in association with anti hypertensive therapy.
In CoGNIPRes, a crosssectional study of 1,579 patients, 80 the prevalence of cognitive impairment defined by low MMse scores was 12.3%. Low MMse scores were associated with age >80 years, uncontrolled BP, and poor compliance to antihypertensive treatment, in addition to history of anxiety, stroke, or transient ischemic attack, and other comorbidities. overall, BP was controlled only in 28.3% of participants, and 33.6% showed poor adherence to antihypertensive treatment. In a prospective community based cohort of individuals aged >65 years residing in Northern Manhattan, usA, hypertension was associated with an increased risk of all cause MCI and non amnestic MCI, but not with amnestic MCI. 81 Hypertension was related to worse executive ability scores, but not to worse memory or language scores, which confirms the specific link between high BP and executive function and attention.
Hypotension and risk of cognitive decline orthostatic hypotension affects about 7% of the normo tensive elderly population and >30% of those aged >75 years who have other conditions such as diabetes, cardiac diseases, or Parkinson disease. 82 orthostatic hypotension increases the risk of stroke, falls, and cognitive decline, 82 regardless of whether the BP drop is systolic or diastolic and regardless of baseline BP (Table 4) . 83, 84 In the ARIC study, 84 the effect of orthostatic hypo tension on several cognitive domains was assessed in a cohort of 12,702 participants over 12 years of follow up. Participants with orthostatic hypotension were more likely to be in the lowest quartile of the Digit symbol substitution Test and the Word Fluency Test scores. However, this association was not independent of other cardio vascular and socioeconomic factors.
With orthostatic hypotension, the maintenance of adequate cerebral perfusion at low BP levels depends on autoregulation. Hypoperfusion can develop with impaired autoregulation, or when BP is low, or when BP falls below the autoregulation range, and can lead to cog nitive decline. Among patients with BP in the lower normal range or hypotension (systolic BP <120 mmHg, diastolic BP <70 mmHg), orthostatic hypotension increases the odds of cognitive impairment (measured ReVIews as >1 MMse score decline; oR = 4.1, 95% CI 1.11-15.1). 81 This effect might be explained by the fact that, in patients with hypotension, perfusion could decline as BP falls below the autoregulated range. By contrast, among patients with hypertension (systolic BP >140 mmHg, diastolic BP >90 mmHg), the presence of orthostatic hypotension reduces the odds of cognitive impairment (oR = 0.48, 95% CI 0.26-0.90). 85 In patients with hyper tension, perfusion can remain within the autoregulated range, or even increase, owing to compensatory vaso dilation in response to orthostatic hypotension. of note, patients with orthostatic hypotension typically have hypertension when in the supine position.
In the Malmö Preventive Project (MPP), 86 the relation ship between orthostatic hypotension and longterm morbidity was assessed in 722 men aged 52.6 ± 3.6 years over a followup period of 19 ± 5.3 years. 5 years after enrollment, 9.9% of participants had orthostatic hypo tension; in 64.5% of the cases of orthostatic hypo tension, a decline in systolic BP, but not in diastolic BP, was observed. orthostatic hypotension was independently associated with age, low BMI, hypertension, increased heart rate, anti hypertensive treatment, diabetes, and current smoking. Men with orthostatic hypotension had an increased risk of coronary events, stroke, and allcause mortality, as shown in a multivariate adjusted Cox proportional hazard model. Furthermore, partici pants with orthostatic hypotension, both at baseline and during followup, were at the highest risk of any adverse event among the study population (oR = 1.76, 95% CI 1.28-2.43). 86 The Helsinki Aging study, 87 which involved 650 people aged 75-85 years, also found that participants with low general BP had low MMse scores (<24), whereas hypertension was found to be unrelated to cognitive impairment. In this study, baseline assess ments showed that participants with dementia had lower BP than those without dementia and also had signs of left ventricular dysfunction.
BP changes late in life could be the consequence of brain degeneration, or might also be its cause. Declining BP and orthostatic hypotension late in life are markers of general frailty, as they indicate underlying autonomic failure associ ated with diabetes, Alzheimer disease, Parkinson disease with dementia, Lewy body dementia, and other disorders. The loss of central autonomic regu lation and perfusion regulation in late age, which alter the BP-perfusion relationship in the setting of hypo tension, might have a broad impact on cognitive networks and, ultimately, on morbidity and mortality. The link between these factors, however, remains unclear. The influence of BP on dementia studies evaluating the relationship between BP, vascular dementia, and Alzheimer dementia have yielded inconsis tent results (Table 5) . Whether low BP leads to Alzheimer disease or whether Alzheimer disease triggers hypo tension is still debated. Crosssectional and longitudinal data of a biracial population aged 60-96 years supported a nonlinear, ushape relationship between low scores on neuropsychological tests and BP values <140 mmHg and >180 mmHg. 43, 88 The prevalence of Alzheimer disease was higher among people with systolic BP <130 mmHg and diastolic BP <70 mmHg than in the reference group (systolic BP 130-139 mmHg). 43, 88 The Honolulu Aging study showed that high systolic BP (the group with 120-140 mmHg and the group with >140 mmHg) in midlife increases the risk of latelife dementia. 89 Men who developed dementia had an addi tional ageadjusted increase in systolic BP of 0.26 mmHg (95% CI 0.01-0.51 mmHg) from midlife to late life and a greater decrease in systolic BP in late life. up to 58% of those with dementia experienced a systolic BP decrease of ≥10 mmHg in late life. The risk ratio [RR] for demen tia was lower in patients treated for hypertension than in untreated patients (RR = 0.76, 95% CI 0.65-0.93 and RR = 1.05, 95% CI 0.86-1.27, respectively). 66 In the oPTIMA study, 90 cognitive function was pro spectively evaluated using the Cambridge Cognitive examination (CAMCoG) tool in 235 cognitively healthy participants, 42 with MCI, 141 with Alzheimer disease, and 59 with other dementia syndrome. In patients with Alzheimer disease, the rate of decline of CAMCoG scores showed a nonlinear, inverted ushaped dependence on diastolic BP. Both low and high diastolic BP levels (<60 mmHg and >110 mmHg) were related to faster cogni tive decline over 5 years of followup (z = -2.51, P = 0.012). CAMCoG scores also showed an inverted ushaped rela tionship between pulse pressure and faster progression of Alzheimer disease (z = -2.29, P = 0.022). In another study, 90 low diastolic BP (<70 mmHg) was associated with a multi adjusted hazard ratio (HR) of 2.13 (95% CI 1.05-4.32) for incidence of dementia and 2.16 (95% CI 0.98-4.73) for incidence of Alzheimer disease in people aged >80 years over 9-16 years of followup, when compared with normal diastolic BP (70-89 mmHg). By contrast, higher dia stolic BP (≥90 mmHg) was only marginally related to a decreased risk of dementia (HR 0.58, 95% CI 0.33-1.02) and of Alzheimer disease (HR 0.57, 95% CI 0.30-1.09). systolic pressure was not significantly related to dementia risk. 90 some studies suggest that BP decline could precede the onset of dementia by at least 3 years, 4 supporting a link between abnormalities in autonomic regulation of BP and dementia risk. In addition, other vascular risk factorsespecially high BMI-might interact with BP to increase the risk of dementia. 91 
Antihypertensive therapy and cognition
Clinical trials in which the impact of anti hypertensive therapy on cognitive outcomes was assessed have had conflicting results (Table 6 ). In the earliest trials, such as the sHeP (systolic Hypertension in the elderly Program) 92 and the Medical Research Council study, 93 no difference in cognitive function was observed between participants who were treated with antihypertensives and those who were untreated. Later, the systeur (systolic Hypertension in europe) trial showed that hypertension treatment with a calciumchannel blocker was associated with a 50% reduction in the risk of developing dementia. 94, 95 More recently, the PRoGRess (Perindopril Protection Against Recurrent stroke study) [96] [97] indicated that treat ment of hypertension with angiotensinconverting enzyme (ACe) inhibitors in patients with previous cerebro vascular disease reduced the risk of dementia and reduced progression of microvascular disease. Patients who were randomly assigned to receive the ACe inhibi tor had a 34% relative risk reduction of the composite outcome of dementia with recurrent strokes (95% CI 3-55%, P = 0.03). similarly, the HoPe (Heart outcomes Prevention evaluation) trial 98, 99 found that ACe inhibitors were associated with a 41% reduction in cognitive decline related to stroke. The sCoPe (study on Cognition and Prognosis in the elderly) trial, 100, 101 which used the MMse to assess cognitive outcome, did not, however, demon strate a difference between the cognitive function of participants randomly assigned to receive an angiotensin receptor blocker (ARB) and those not given an ARB. In this study, the group receiving candersartan showed less decline in attention than the group not receiving an ARB, but no differences in working memory were observed. 102 A major concern related to this trial is that many patients assigned to the 'control' group were already receiving antihypertensive therapy, including ARBs.
In the very elderly (>75 years old), the effect of anti hypertensive therapy is even more inconclusive. In HYveTCoG, 76, 77 treatment with an ACe inhibitor had no effect on dementia risk or cognitive decline. However, the median followup of this study was only 2 years; the trial was terminated prematurely, because treatment resulted in a 41% decrease in the primary end point of fatal or nonfatal stroke. of 4,695 randomly assigned patients, 2,418 participated in the substudy on dementia.
No other study has been designed to address this issue in very elderly individuals.
The combined results of these trials are also not conclu sive A pooled analysis of the PRoGRess, sCoPe, sHeP, and systeur trials, whose participants in the treatment group total 11,794 and those in the control group total 11,711, revealed a nonsignificant associ ation between antihypertensive treatment and the risk of developing dementia (oR 0.89, 95% CI 0.75-1.04). 103 The hetero geneity measure in this analysis was high, however, and the results were not robust. A metaanalysis of published trials, including HYveT, 75 demonstrated that, when com bined, these studies point to a protective effect of anti hypertensive therapy on cognition. 75, 77 However, more recently published trials do not corroborate these find ings. For example, in the PRoFess trial, 104 which used a 2 × 2 factorial design, ARB therapy did not provide cog nitive protection after stroke. In addition, results from the oNTARGeT trial 105 suggest that systolic BP lower ing below the 130-150 mmHg range using ramipril and telmi sartan does not improve outcomes.
The inconsistencies in the results of these trials, indivi dually or when combined in metaanalyses, are likely to be related to differences in the age and, more impor tantly, in the baseline cognitive function of the popula tions studied. The cognitive domain being measured is also likely to be an important cause of the observed hetero geneity. Furthermore, many of the trials have used MMse, a fairly insensitive and nonspecific measure of cognitive change. 106 Hypertension, however, is more likely to be related to executive function than to overall cogni tive performance. [107] [108] [109] Pharmacogenetic variation in cognitive responses, pharmacokinetic characteristics of antihypertensive agents, and study duration are additional factors that lead to heterogeneity in studies of hyper tension therapy and cognitive function. A meta analysis of random ized controlled trials of antihypertensive therapy in the elderly indicated that BP reduction lowers the risk of stroke (35%), cardiovascular events (27%), and heart failure (50%), but does not affect mortality. 110 By contrast, small BP reductions and low intensity of therapy were associated with decreased mortality. 110 some studies have compared the outcomes achieved with different classes of antihypertensive therapy. The us veteran Affairs study 111 determined prospectively that ARBs are more effective in lowering the risk of Alzheimer disease and any dementia compared with the ACe inhibitor lisinopril or other classes of cardio vascular medications. other trials that assessed the impact of ARBs on cognitive function demonstrated a superior effect of this class of drugs in comparison with the βblocker atenolol, 112 and with the combination of hydrochlorothiazide and lisinopril. 113 Antihypertensive drugs such as ACe inhibitors (perindopril, captopril), ARBs (losartan), 112, 114 and calciumchannel blockers (nitrendipine) possibly have classspecific effects, and combination therapy might increase cognitive protec tion. Pharmacokinetic differences within a drug class might also explain this heterogeneity. For example, in the Cardiovascular Health study, 115 ACe inhibitors that cross the blood-brain barrier provide cognitive protection, which is not observed with ACe inhibitors that do not cross the blood-brain barrier. studies of anti hypertensive therapy suggest that antihypertensive treatment might be protective against vascular diseases and some of their con sequences in the brain. The BP targets that would be pro tective against cognitive decline remain to be determined in future trials.
Conclusions
substantial evidence exists supporting the link between BP and cognition. This relationship might be mediated by impairment of vascular reserve and microvascular disease. Both hypertension and hypotension contribute to cognitive decline, and a combination of vascular risk factors during an individual's lifetime could accelerate functional cognitive loss later in life. Combined anti hypertensive therapy could have protective effects on vascular disease and cognition. effective approaches for prevention of cognitive decline, risk reduction, and exten sion of survival are needed for treatment of hypertension in old age. 
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